Skip to main content

tovecimig

Generic: Tovecimig·Code: CTX-009

tovecimig: developed by 1 company · 5 clinical trials tracked.

tovecimig evidence translation

What we can confirm

What it means

Source-backed records connect tovecimig to CMPX; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could tovecimig → CMPX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (3)
CompanyPhase
Compass Therapeutics, Inc. (CMPX)Phase 2/Phase 3
Compass Therapeutics, Inc. (CMPX)Phase 3
Compass Therapeutics, Inc. (CMPX)
Biliary Tract Cancer; Metastatic Colorectal Cancer
Phase 2
Clinical Trials (5)

A Phase 2 Clinical Trial of Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer

NCT07662031·Phase 2
Not yet recruiting

Primary endpoint: Overall Response Rate (ORR)

Interventionalopen25 targetStarted 2026-08Completion 2032-081 site · United StatesWashington University School of Medicine

A Phase IB/II Open-label Study of the Safety and Preliminary Efficacy of CTX-009 Administered Either as a Monotherapy or in Combination With CTX-471 in Patients With Recurrent Glioblastoma

NCT07392957·Phase 1/Phase 2
Recruiting

Primary endpoint: Phase IB Arm 1: Toxicity as measured by number of participants with adverse events

InterventionalRandomizedopen54 targetStarted 2026-06Completion 2031-061 site · United StatesWashington University School of Medicine

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

NCT06548412·Phase 1/Phase 2
Recruiting

Primary endpoint: Safety and Adverse Events (AEs)

InterventionalRandomizedopen50 targetStarted 2025-01Completion 2029-051 site · United StatesM.D. Anderson Cancer Center

A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen

NCT05506943·Phase 2/Phase 3·CMPX
Active, not recruiting

Primary endpoint: Best Overall Response

InterventionalRandomizedsingle168 targetStarted 2023-01Completion 2026-1234 sites · United StatesCompass Therapeutics

A Phase 2 Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer Who Have Received Two or Three Prior Systemic Chemotherapy Regimens

NCT05513742·Phase 2·CMPX
Completed

Primary endpoint: Overall Response Rate

Interventionalopen49 enrolledStarted 2022-12Completion 2025-057 sites · United StatesCompass Therapeutics

Frequently asked questions

Who is developing tovecimig?

tovecimig is being developed by Compass Therapeutics, Inc..

How many clinical trials involve tovecimig?

BioSniper tracks 5 clinical trials involving tovecimig.